BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 19429869)

  • 21. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
    Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B
    Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular synergy underlies the co-occurrence patterns and phenotype of
    Dovey OM; Cooper JL; Mupo A; Grove CS; Lynn C; Conte N; Andrews RM; Pacharne S; Tzelepis K; Vijayabaskar MS; Green P; Rad R; Arends M; Wright P; Yusa K; Bradley A; Varela I; Vassiliou GS
    Blood; 2017 Oct; 130(17):1911-1922. PubMed ID: 28835438
    [No Abstract]   [Full Text] [Related]  

  • 23. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
    Schneider F; Hoster E; Schneider S; Dufour A; Benthaus T; Kakadia PM; Bohlander SK; Braess J; Heinecke A; Sauerland MC; Berdel WE; Buechner T; Woermann BJ; Feuring-Buske M; Buske C; Creutzig U; Thiede C; Zwaan MC; van den Heuvel-Eibrink MM; Reinhardt D; Hiddemann W; Spiekermann K
    Ann Hematol; 2012 Jan; 91(1):9-18. PubMed ID: 21744003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis.
    Chen CY; Chou WC; Tsay W; Tang JL; Yao M; Huang SY; Tien HF
    BMC Cancer; 2013 Mar; 13():107. PubMed ID: 23496932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fms like tyrosine kinase (FLT3) and nucleophosmin 1 (NPM1) mutations in de novo normal karyotype acute myeloid leukemia (AML).
    Dunna NR; Rajappa S; Digumarti R; Vure S; Kagita S; Damineni S; Rao VR; Yadav SK; Ravuri RR; Satti V
    Asian Pac J Cancer Prev; 2010; 11(6):1811-6. PubMed ID: 21338238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
    Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
    Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.
    Schnittger S; Kern W; Tschulik C; Weiss T; Dicker F; Falini B; Haferlach C; Haferlach T
    Blood; 2009 Sep; 114(11):2220-31. PubMed ID: 19587375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutation of NPM1 and FLT3 genes in acute myeloid leukemia and their association with clinical and immunophenotypic features.
    Chauhan PS; Ihsan R; Singh LC; Gupta DK; Mittal V; Kapur S
    Dis Markers; 2013; 35(5):581-8. PubMed ID: 24288427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
    Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The surface molecular signature of leukemic cells is associated with NPM1 mutations and FLT3 -ITD in patients with de novo acute myeloid leukemia.
    Su L; Gao SJ; Li W; Tan YH; Cui JW; Han W
    Acta Haematol; 2014; 131(3):148-52. PubMed ID: 24192815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
    Falini B; Martelli MP; Bolli N; Sportoletti P; Liso A; Tiacci E; Haferlach T
    Blood; 2011 Jan; 117(4):1109-20. PubMed ID: 21030560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia.
    Kühn MW; Song E; Feng Z; Sinha A; Chen CW; Deshpande AJ; Cusan M; Farnoud N; Mupo A; Grove C; Koche R; Bradner JE; de Stanchina E; Vassiliou GS; Hoshii T; Armstrong SA
    Cancer Discov; 2016 Oct; 6(10):1166-1181. PubMed ID: 27535106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytogenetic abnormalities in
    Fu W; Huang A; Xu L; Peng Y; Gao L; Chen L; Chen J; Tang G; Yang J; Ni X
    Leuk Lymphoma; 2022 Aug; 63(8):1956-1963. PubMed ID: 35227153
    [No Abstract]   [Full Text] [Related]  

  • 34. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.
    Mason EF; Hasserjian RP; Aggarwal N; Seegmiller AC; Pozdnyakova O
    Blood Adv; 2019 Nov; 3(21):3322-3332. PubMed ID: 31698462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What Is Abnormal in Normal Karyotype Acute Myeloid Leukemia in Children? Analysis of the Mutational Landscape and Prognosis of the TARGET-AML Cohort.
    Herlin MK; Yones SA; Kjeldsen E; Holmfeldt L; Hasle H
    Genes (Basel); 2021 May; 12(6):. PubMed ID: 34064268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HOX expression patterns identify a common signature for favorable AML.
    Andreeff M; Ruvolo V; Gadgil S; Zeng C; Coombes K; Chen W; Kornblau S; Barón AE; Drabkin HA
    Leukemia; 2008 Nov; 22(11):2041-7. PubMed ID: 18668134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype.
    Schneider F; Hoster E; Unterhalt M; Schneider S; Dufour A; Benthaus T; Mellert G; Zellmeier E; Kakadia PM; Bohlander SK; Feuring-Buske M; Buske C; Braess J; Heinecke A; Sauerland MC; Berdel WE; Büchner T; Wörmann BJ; Hiddemann W; Spiekermann K
    Blood; 2012 May; 119(19):4383-6. PubMed ID: 22374696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [FLT3 and NPM1 gene mutations in patients with acute myeloid leukemias and the impact of FLT3-ITD mutations on the survival of patients with a normal karyotype].
    Martynkevich IS; Gritsaev SV; Moskalenko MV; Ivanova MP; Aksenova VIu; Tiranova SA; Abdulkadyrov KM
    Ter Arkh; 2010; 82(12):33-9. PubMed ID: 21516736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4.
    Herold T; Metzeler KH; Vosberg S; Hartmann L; Jurinovic V; Opatz S; Konstandin NP; Schneider S; Zellmeier E; Ksienzyk B; Graf A; Krebs S; Blum H; Cristina Sauerland M; Büchner T; Berdel WE; Wörmann BJ; Mansmann U; Hiddemann W; Bohlander SK; Spiekermann K; Greif PA
    Genes Chromosomes Cancer; 2017 Jan; 56(1):75-86. PubMed ID: 27636548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].
    Liu YR; Chang Y; Ruan GR; Qin YZ; Lai YY; Shi HX; Wang YZ; Li LD; Jiang B; Li JL
    Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):98-103. PubMed ID: 23611213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.